Skip to main content
. Author manuscript; available in PMC: 2024 Feb 5.
Published in final edited form as: Nat Neurosci. 2023 Jul 13;26(8):1417–1428. doi: 10.1038/s41593-023-01390-9

Extended Data Fig. 5 |. Drug effects on D1-/D2-SPN Ca2+ event amplitudes under normal and hyperdopaminergic conditions.

Extended Data Fig. 5 |

a–c, Mean ± s.e.m. Ca2+ event amplitudes of D1- and D2-SPNs across all speeds following treatment with haloperidol, olanzapine, clozapine, or MP-10 (a), xanomeline, VU0467154, or SEP-363856 (b), and SKF39393, SCH23390, or SCH39166 (c), normalized to values following vehicle only treatment. Data are from periods before (top) or after (bottom) amphetamine treatment. Heat maps depict the mean D1- and D2-SPN Ca2+ event amplitudes, normalized to values following vehicle only treatment (Drug/Vehicle) and the vehicle-normalized values, normalized to the corresponding value following vehicle + amphetamine treatment (Drug/Amph; ****P < 10−4, ***P < 10−3, **P < 10−2 and *P < 0.05 for comparison to vehicle treatment; ####P < 10−4, ###P < 10−3, ##P < 10−2 and #P < 0.05 compared vehicle + amphetamine treatment; One-way ANOVA with Holm-Sidak’s multiple comparison test).